BioArctic AB's partner Eisai announced that Leqembi® generic name: lecanemab has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. China is the third country to launch Leqembi following the United States and Japan.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent for Cyklokapron® as approved by the U.S. Food and Drug Administration.
Bruker Corporation (Nasdaq: BRKR) launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, it has launched Isoproterenol Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for ISUPREL® as approved by the U.S. Food and Drug Administration. Isoproterenol Hydrochloride Injection, USP is indicated.
ChromaDex Corp. the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, launched its flagship consumer supplement, Tru Niagen®,